Abstract: TH-OR070
Clonal Hematopoiesis and AKI in Estrogen-Dependent Cancers
Session Information
- Onconephrology: Updates, Therapies, and Mechanisms
November 06, 2025 | Location: Room 371A, Convention Center
Abstract Time: 05:30 PM - 05:40 PM
Category: Onconephrology
- 1700 Onconephrology
Authors
- Won, Alice H., Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Ruthen, Neil, Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Tan, Hui Zhuan, Singapore General Hospital, Singapore, Singapore
- Reznik, Ed, Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Jaimes, Edgar A., Memorial Sloan Kettering Cancer Center, New York, New York, United States
Background
Clonal hematopoiesis of indeterminate potential (CHIP) has been linked to a higher risk for acute kidney injury (AKI) in the general population. However, whether CHIP confers increased risk for AKI independent of known cancer-associated risk factors remains unknown
Methods
From a single institutional database, we identified 24,811 patients with solid tumors, with longitudinal serum creatinine ([sCr]) values, targeted sequencing of paired tumor and blood samples (MSKCC-IMPACT), and well-documented treatments. We performed competing risk analyses over Cox proportional hazards models to test for the association of CHIP and time to AKI from the date of blood sample collection, adjusting for other risk factors
Results
We report that mutations in PPM1D and other DNA damage response (DDR) genes are significantly associated with decreased time to AKI in breast, endometrial, ovarian, and non-small cell lung cancers. As the estrogen receptor is a transcriptional regulator of DDR genes, we further demonstrate that receipt of estrogen receptor antagonists and selective estrogen receptor modulators is associated with decreased risk of AKI
Conclusion
Our study reveals specific CHIP mutations as prognostic markers for AKI in the context of specific tumor-associated physiologies